Mechanistic Pathways of Selenium in the Treatment of Graves’ Disease and Graves’ Orbitopathy

Marinò, Michele; Dottore, Giovanna Rotondo; Leo, Marenza; Marcocci, Claudio

doi:10.1055/a-0658-7889

Cited by 18 publications

(13 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The choice of treatment depends on the extent of GO activity, which is defined by a clinical activity score (1,22). Patients affected with mild GO can be treated with lubricants and/or selenium (1,23,24), whereas, according to the European Group On Graves' Orbitopathy (EUGOGO) guidelines, high dose intravenous glucocorticoids GC (ivGC) are the first line treatment for moderately severe and active GO (1). However, more recently, new medications have been proposed, including rituximab (25), teprotumumab (26,27), mycophenolate (28), and tocilizumab (29).…”

Section: Brief Notes On Gomentioning

confidence: 99%

Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy

et al. 2020

Self Cite

View full text Add to dashboard Cite

Graves' Orbitopathy (GO) is the most frequent extrathyroidal manifestation of Graves' disease (GD). Its ultimate cause remains unclear, but it is commonly considered an autoimmune disorder due to self recognition of autoantigens constitutively expressed by orbital fibroblasts (OFs), and thyroid epithelial cells. High dose intravenous glucocorticoids (ivGC) are the most commonly used treatment for moderately severe and active GO. However, based on the complex pathogenesis of GO, a number of factors may have a protective and maybe a therapeutic role. The use of other medications improving the effect of GC may increase the overall effectiveness of the therapy and reduce GC doses, thereby limiting side effects. Recently, a possible protective role of 3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors, the so-called statins, and perhaps of lowering cholesterol levels, has been proposed. Thus, statins have been reported to be associated with a reduced frequency of GO in GD patients and in recent cross-sectional and retrospective studies a significant correlation was found between the occurrence of GO and both total and LDL-cholesterol in patients with a GD of relatively recent onset, suggesting a role of cholesterol in the development of GO. Moreover, a correlation was found between the GO clinical activity score and total as well as LDL-cholesterol in untreated GO patients, depending on GO duration, indicating a role of cholesterol on GO activity. Therefore, statin treatment may be beneficial for GO. Here we review this subject, which offers new therapeutic perspectives for patients with GO.

show abstract

Section: Brief Notes On Gomentioning

confidence: 99%

Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…ДТЗ на сегодняшний день является единственным заболеванием, в случае которого Se помогает контролировать тиреотоксикоз при совместном приеме с тиреостатическими препаратами, правда в этом случае специалисты рекомендуют добавлять селен только тем, у кого есть документально подтвержденный дефицит Se. В настоящее время продолжается исследование GRASS, которое должно ответить на вопросы, позволит ли добавление селена к терапии болезни Грейвса ускорить достижение эутиреоза, снизить риск рецидива заболевания, улучшить качество жизни больных [43][44][45][46][47].…”

Section: диффузный токсический зоб (дтз) или болезнь грейвса-базедоваunclassified

Селен И Здоровье Человека

Rakov¹,

Muz²

2019

Endokr.

View full text Add to dashboard Cite

В обзоре дана характеристика основных путей метаболизма селена в организме человека. Показано, что основной биологической ролью селена у эукариот является его участие в синтезе и регуляции активности ряда ферментов (глутатионпероксидаз, селензависимой пероксидазы, белков семейств селенопротеинов P и W,5`-йодотирониндейодиназ, тиоредоксинредуктазы). В последние годы эндокринологи Украины стали активно назначать препараты селена при любых проблемах со щитовидной железой. Мы не являемся сторонниками такого лечения, а считаем необходимым назначение селеносодержащих препаратов только при исходно низком содержании селена в организме человека. Правильность этого мнения находит свое подтверждение и в ряде статей зарубежной литературы. В обзоре авторы сделали попытку обобщить научно обоснованную информацию о том, когда нужно принимать селен, а когда нет, и почему возникла такая практика в принципе

show abstract

“…Most recently, we also focused on thyroid diseases, e. g. autoimmune thyroid disease; here another three special issues were published highlighting the genetic cause as well as the immunological background, diagnostic procedures and therapeutic options in Graves' disease and autoimmune thyroiditis, including a most recent special issue [16][17][18][19][20][21][22][23][24].…”

Section: Dear Readersmentioning

confidence: 99%